Production (Stage)
ZYUS Life Sciences Corporation
ZLSCF
$0.5046
-$0.0454-8.26%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 22.45% | -50.28% | -32.93% | -66.68% | -66.03% |
| Total Depreciation and Amortization | -6.09% | 41.89% | 22.97% | -3.15% | -3.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.85% | 99.25% | 53.98% | 140.30% | 203.01% |
| Change in Net Operating Assets | 136.17% | 194.96% | -191.35% | -376.88% | -274.86% |
| Cash from Operations | 46.29% | 57.34% | -36.60% | -122.37% | -80.28% |
| Capital Expenditure | 83.59% | 34.19% | 37.35% | 54.16% | 51.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -100.00% | -100.00% | 15,622.03% | 15,622.03% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,948.30% | -- | -- | -- | -- |
| Cash from Investing | -61.73% | -106.56% | -107.19% | 854.62% | 860.24% |
| Total Debt Issued | -73.17% | -97.03% | -98.45% | 91.26% | 116.85% |
| Total Debt Repaid | 25.92% | 14.53% | 63.18% | -1,178.43% | -1,096.79% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -66.42% | -96.74% | -104.09% | 49.30% | 71.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -155.90% | -196.71% | -196.06% | -84.73% | 763.18% |